Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR070803 combinations in resected pancreatic cancer
NCT06383078Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules, Lipid-based Nanoparticles
01
Overview
A Phase 2 trial of CPO-120 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Jiangsu Provincial People's Hospital. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
CPO-120
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06383078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383078.